Literature DB >> 24958328

DNA hypermethylation and X chromosome inactivation are major determinants of phenotypic variation in women heterozygous for G6PD mutations.

Jin Wang1, Qi-Zhi Xiao2, You-Ming Chen3, Sheng Yi1, Dun Liu1, Yan-Hui Liu4, Cui-Mei Zhang5, Xiao-Feng Wei1, Yu-Qiu Zhou2, Xing-Ming Zhong6, Cun-You Zhao1, Fu Xiong1, Xiang-Cai Wei7, Xiang-Min Xu8.   

Abstract

Glucose-6-phosphate dehydrogenase (G6PD) deficiency is an X-linked incompletely dominant enzyme deficiency that results from G6PD gene mutations. Women heterozygous for G6PD mutations exhibit variation in the loss of enzyme activity but the cause of this phenotypic variation is unclear. We determined DNA methylation and X-inactivation patterns in 71 G6PD-deficient female heterozygotes and 68 G6PD non-deficient controls with the same missense mutations (G6PD Canton c.1376G>T or Kaiping c.1388G>A) to correlate determinants with variable phenotypes. Specific CpG methylations within the G6PD promoter were significantly higher in G6PD-deficient heterozygotes than in controls. Preferential X-inactivation of the G6PD wild-type allele was determined in heterozygotes. The incidence of preferential X-inactivation was 86.2% in the deficient heterozygote group and 31.7% in the non-deficient heterozygote group. A significant negative correlation was observed between X-inactivation ratios of the wild-type allele and G6PD/6-phosphogluconate dehydrogenase (6PGD) ratios in heterozygous G6PD Canton (r=-0.657, p<0.001) or Kaiping (r=-0.668, p<0.001). Multivariate logistic regression indicated that heterozygotes with hypermethylation of specific CpG sites in the G6PD promoter and preferential X-inactivation of the wild-type allele were at risk of enzyme deficiency.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  G6PD; Methylation; Phenotypic variation; Women heterozygous; X chromosome inactivation

Mesh:

Substances:

Year:  2014        PMID: 24958328     DOI: 10.1016/j.bcmd.2014.06.001

Source DB:  PubMed          Journal:  Blood Cells Mol Dis        ISSN: 1079-9796            Impact factor:   3.039


  6 in total

1.  The Elderly with Glucose-6-Phosphate Dehydrogenase Deficiency are More Susceptible to Cardiovascular Disease.

Authors:  Maria Pina Dore; Michele Portoghese; Giovanni Mario Pes
Journal:  J Atheroscler Thromb       Date:  2020-09-10       Impact factor: 4.928

2.  Diagnosis and Treatment of Plasmodium vivax Malaria.

Authors:  J Kevin Baird; Neena Valecha; Stephan Duparc; Nicholas J White; Ric N Price
Journal:  Am J Trop Med Hyg       Date:  2016-10-05       Impact factor: 2.345

3.  G6PD variant distribution in sub-Saharan Africa and potential risks of using chloroquine/hydroxychloroquine based treatments for COVID-19.

Authors:  Jorge da Rocha; Houcemeddine Othman; Caroline T Tiemessen; Gerrit Botha; Michele Ramsay; Collen Masimirembwa; Clement Adebamowo; Ananyo Choudhury; Jean-Tristan Brandenburg; Mogomotsi Matshaba; Gustave Simo; Francisco-Javier Gamo; Scott Hazelhurst
Journal:  medRxiv       Date:  2020-06-02

4.  Erythrocyte glucose-6-phosphate dehydrogenase activity and risk of gestational diabetes.

Authors:  Parvaneh Asadi; Mahmood Vessal; Marjan Khorsand; Mohammad Ali Takhshid
Journal:  J Diabetes Metab Disord       Date:  2019-11-27

5.  G6PD distribution in sub-Saharan Africa and potential risks of using chloroquine/hydroxychloroquine based treatments for COVID-19.

Authors:  Jorge E B da Rocha; Houcemeddine Othman; Caroline T Tiemessen; Gerrit Botha; Michèle Ramsay; Collen Masimirembwa; Clement Adebamowo; Ananyo Choudhury; Jean-Tristan Brandenburg; Mogomotsi Matshaba; Gustave Simo; Francisco-Javier Gamo; Scott Hazelhurst
Journal:  Pharmacogenomics J       Date:  2021-07-23       Impact factor: 3.550

6.  Genotype-Phenotype Correlation of G6PD Mutations among Central Thai Children with G6PD Deficiency.

Authors:  Boonchai Boonyawat; Tim Phetthong; Nithipun Suksumek; Chanchai Traivaree
Journal:  Anemia       Date:  2021-02-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.